Compilers of nanotech stock indices will be smacking their lips at the prospect of another publicly quoted nanotechnology company. Others may be concerned at yet another small cap play, but the founders and investors in Oxonica will no doubt be happy.
As a company with products and some sales, it will be interesting to see the reaction of the UK AIM market to nanotech, although whether nanotechnology will command a premium remains to be seen. Charlie Harris of the eponymous Harris and Harris explains why.